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Abstract
Objective: We previously reported that genetic variants in SORCS1 increase the risk of AD, that over-expression of SorCS1
reduces c-secretase activity and Ab levels, and that SorCS1 suppression increases c-secretase processing of APP and Ab
levels. We now explored the effect of variation in SORCS1 on memory.
Methods: We explored associations between SORCS1-SNPs and memory retention in the NIA-LOAD case control dataset
(162 cases,670 controls) and a cohort of Caribbean Hispanics (549 cases,544 controls) using single marker and haplotype
analyses.
Results: Three SNPs in intron 1, were associated with memory retention in the NIA-LOAD dataset or the Caribbean Hispanic
dataset (rs10884402(A allele:b = 20.15,p=0.008), rs7078098(C allele:b =0.18,p=0.007) and rs950809(C alle-
le:b=0.17,p=0.008)) and all three SNPs were significant in a meta-analysis of both datasets (0.002,p,0.03). The
corresponding A-T-T haplotype for these SNPs was associated with lower scores in both datasets (p=0.02,p=0.0009), and
the complementary G-C-C haplotype was associated with higher scores in NIA-LOAD (p=0.02). These associations were
restricted to cases.
Conclusions: Variation in intron 1 in SORCS1 is associated with memory changes in AD.
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Introduction
The putative culprit in Alzheimer’s disease (AD) is the amyloid
b (Ab) protein. It is produced by b-secretase (BACE) cleavage of
the amyloid precursor protein (APP) at the N-terminus of the Ab
peptide followed by c-secretase cleavage of the membrane-bound
C-terminal APP fragment [1]. APP and the secretases are integral
transmembrane proteins, and are dynamically sorted into the
plasma membrane and the membranes of intracellular organelles
[2,3]. As a consequence, sorting mechanisms that cause APP and
the secretases to colocalize in the same cellular compartment are
expected to play important roles in the regulation of Ab
production.
We and several other groups have recently reported [4,5,6] that
variants in the sortilin-related VPS10 domain containing receptor
1( SORCS1), which maps to chromosome 10q23–25, are associated
with AD. We also demonstrated that over expression of SorCS1
reduces c-secretase activity and Ab levels, and that suppression of
SorCS1 increases c-secretase processing of APP and the levels of
Ab. SORCS1 belongs to the mammalian Vps10p-domain sorting
receptor family, which is a group of five type I membrane
homologues (SORL1, Sortilin, SorCS1, SorCS2, and SorCS3)
[7,8,9,10]. The common characteristic of these receptors is an N-
terminal Vps10p domain, which either represents the only module
of the luminal/extracellular moiety or is combined with additional
domains. The individual receptors bind and internalize a variety of
ligands, such as neuropeptides and trophic factors, and Sortilin
and SorLA mediate trans-Golgi network-to-endosome sorting.
Their prominent neuronal expression, several of the identified
ligands, and recent results support the notion that members of this
receptor family have important functions in neurogenesis,
plasticity-related processes, and neuronal activity [11,12] but their
precise function remains elusive.
Based on these findings we hypothesized that genetic variants in
the 59 end in SORCS1 might be associated with changes in
memory performance, the cognitive domain predominately
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whether or not genetic variation in SORCS1 was associated with
memory retention in two independent datasets that have sufficient
power to detect modest effect sizes.
Methods
Participants
Written informed consent was obtained from all subjects
included. Recruitment for the Caribbean Hispanic Study was
approved by the Institutional Review Board of the Columbia
University Medical Center. Recruitment for the NIALOAD Study
was approved by the relevant institutional review boards of the
participating centers (ie. the IRBs of Boston University, Columbia
University, Duke University, Indiana University, Massachusetts
General Hospital, Mayo Clinic, Mount Sinai School of Medicine,
Oregon Health & Science University, Rush University Medical
Center, University of Alabama at Birmingham, University of
California Los Angeles; University of Kentucky; University of
Pennsylvania; University of Pittsburgh; University of Southern
California; University of Texas Southwestern; University of
Washington; Washington University Medical Center; University
of Miami; Northwestern University; Emory University).The study
was conducted according to the principles expressed in the
Declaration of Helsinki.
The two datasets included a) 162 Caucasian cases and 670
controls from the NIA-LOAD study [13] and b) 549 cases and 544
controls from a Caribbean Hispanic dataset that have been
described in detail elsewhere [14]. The clinical characteristics of
these datasets are summarized in Table 1. The diagnoses of
‘probable’ or ‘possible’ AD were defined according to the National
Institute of Neurological and Communication Disorders and
Stroke–Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) diagnosis criteria at clinics specializing in
memory disorders or in clinical investigations. Persons were
classified as ‘‘controls’’ when they were without cognitive
impairment or dementia at last visit. Informed consent was
obtained from all participants using procedures approved by
institutional review boards at each of the clinical research centers
collecting human subjects.
Cognitive assessments
For both studies, all participants underwent a standardized
neuropsychological test battery that examined multiple domains
[15]. In the Caribbean Hispanic Study, orientation was evaluated
using parts of the modified Mini-Mental State Examination [16].
Language was assessed using the Boston Naming Test [17], the
Controlled Word Association Test [18], category naming, and the
Complex Ideational Material and Phrase Repetition subtests from
the Boston Diagnostic Aphasia Evaluation [19]. Abstract Reason-
ing was evaluated using WAIS-R Similarities subtest [20], and the
non-verbal Identities and Oddities subtest of the Mattis Dementia
Rating Scale [21]. Visuospatial ability was examined using the
Rosen Drawing Test [22], and a matching version of the Benton
Visual Retention Test [23]. Memory was evaluated using the
multiple choice version of the Benton Visual Retention Test [23]
and the seven subtests of the Selective Reminding Test [24]: total
recall, long-term recall, long-term storage, continuous long-term
storage, words recalled on last trial, delayed recall, and delayed
recognition. This neuropsychological test battery has established
norms for the same community [25]. In the NIA-LOAD Study,
cognition was measured with a battery of 7 brief tests [26].
Working memory was assessed with Digit Span Forward [27],
Digit Span Backward [27], and Digit Ordering [28]. Two
measures of episodic memory were included: immediate and
delayed recall of story A from the Wechsler Memory Scale-
Revised [27]. Semantic memory was assessed by asking persons to
name members of two semantic categories (Animals, Vegetables)
in separate 1-min trials [26,28,29]. While all subjects recruited into
the NIA-LOAD study underwent standard neuropsychological
assessment that contributed to the diagnosis of AD, the
standardized neuropsychological test battery especially designed
for the NIA-LOAD study was integrated in the study at a later
stage (year 2004). Therefore only 832 subjects of the originally
recruited case-control sample (n=1877) have standardized
neuropsychological data and contributed to the final analytic
NIA-LOAD sample included in the present analysis.
Genotyping
Both study sites provided the results from genotyping of SORCS1
SNPs that were part of its genome-wide studies described
previously [13,14]. For the NIA-LOAD study, SNPs were
genotyped using the Illumina Human610Quadv1_B BeadChips
(Illumina, San Diego, CA, USA). For the Caribbean Hispanic
study, SNPs were genotyped using the Illumina HumanHap 650Y
chip. Genotyping of APOE polymorphisms (based on SNPs rs7412
and rs429358) for all samples was performed at PreventionGe-
netics.
Statistical methods
First, for both datasets a memory savings score was calculated
by dividing Delayed Free Recall by Trial 6 Recall (Caribbean
Hispanic Study) or by Story (NIA-LOAD Study) multiplied by 100
and expressed as a percent. Using the means and standard
deviations from the control samples, we then transformed the
resulting savings scores into z-scores. Then, we restricted the
genotyping data to the SNPs that were overlapping in both
datasets (110 overlappimg SNPs spanning 590 kb). SNP marker
data were assessed for deviations from Hardy-Weinberg equilib-
rium (HWE) in controls. Independently for each dataset,
multivariate linear regression analyses were used to assess
genotypic and allelic associations with the memory savings scores,
adjusting for Population stratification, sex, APOE-e4 and age-at-
onset or age-at-examination. The False Discovery Rate (FDR)
[30], which controls the expected proportion of incorrectly
Table 1. Characteristics of the study samples.
Caribbean Hispanic
Study(n=1,093)
NIA-LOAD Case
Control(n=832)
Characteristics
Affected with AD 549 162
Unaffected 544 670
Age
Onset: affecteds 79.9868.0 71.666.9
Age at last exam:
unaffecteds
78.8766.4 76.168.4
Sex
Proportion of females (%) 69.7 62.3
APOE allele frequency (%)
e4 18.2 31.2
e3 75.1 63.3
e2 6.8 5.5
doi:10.1371/journal.pone.0024588.t001
SORCS1 and Cognition
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e24588rejected null hypotheses (type I errors), was used to account for the
error in multiple comparisons. PLINK (http://pngu.mgh.harvard.
edu/,purcell/plink/) was used to perform a meta-analysis of both
datasets.
We used Haploview (http://www.broad.mit.edu/mpg/haploview/
index.php) to assess linkage disequilibrium (LD). Haplotype blocks
were defined using the confidence intervals algorithm. The default
settings were used in these analyses, which create 95% confidence
bounds on D9 to define SNP pairs in strong LD. Analyses assessing
associations between haplotypes and the memory savings score, were
carried out using a window of three contiguous SNPs using PLINK
v1.07 (http://pngu.mgh.harvard.edu/,purcell/plink/) for case-con-
trol data. We performed all analyses first for cases and controls
combined, and then for the case and control groups separately.
We also performed a meta-analysis of both datasets for single
marker and haplotype analyses. To determine the strength of
associations between the individual SORCS1 SNPs (or haplotypes)
and the memory savings score, we calculated a pooled OR for
each marker/haplotype using fixed and random effects models
using PLINK. We first performed meta-analyses of unadjusted
results from the individual datasets, and then repeated the meta-
analyses using the results from the individual datasets adjusting for
Population stratification, sex, APOE-e4 and age-at-onset or age-
at-examination. The p-values for each SNP/haplotype were
corrected for multiple testing using the False Discovery Rate
(FDR). Between-dataset heterogeneity was quantified using the I
2
metric for inconsistency and its statistical significance was tested
with the chi-square distributed Q statistic. I
2 is provided by the
ratio of (Q2df)/Q, where df=the number of degrees of freedom
(one less than the number of combined datasets); it is considered
large for values above 50% and Q is considered statistically
significant for p=0.10.
Results
Table 1 shows the characteristics of the study populations. In
the NIA-LOAD dataset, 11 SNPs were significantly associated
with the memory savings score after correction for multiple testing
(rs10491052, rs11192998, rs7091546, rs10509823, rs1887635,
rs6584784, rs7078098, rs950809, rs596577, rs7083707,
rs7922128; 0.006,p,0.04) and in the Caribbean Hispanic
dataset two SNPs were associated (rs10884402 (p=0.007) and
rs2149196 (p=0.04)). rs10884402 (A allele associated with lower
scores in the Caribbean Hispanics, table 2), and rs7078098 and
rs950809 (C alleles associated with higher scores in the NIALOD
dataset) constitute a block of three adjacent SNPs that are 2.4 kb
apart and are in LD in both datasets (figures 1a and 1b). In a meta-
analysis of both datasets, all three SNPs were significantly
associated with the savings score (table 2): corresponding to the
separate analyses of both datasets, the A allele of rs10884402 was
associated with lower scores, while the C alleles of rs7078098 and
rs950809 were associated with higher scores. When the analyses
were stratified by AD status, the associations of all 3 SNPs was
driven by cases and not present in the controls (table 2). When the
analyses were stratified by APOEe4 carrier status, the associations
were similar in both APOE groups.
Consistent with the single marker analyses, in the 3-SNP sliding
window haplotype analyses the corresponding ATT haplotype for
SNPs rs10884402|rs7078098|rs950809 were associated with
lower scores in both datasets (table 3). In addition, the
complementary GCC haplotype was associated with higher scores
in the NIA-LOAD dataset. Again, these associations held up in
meta-analyses of both datasets, were driven by cases, and not
influenced by APOe4 carrier status.
Discussion
The findings reported here suggest that genetic variation in
SORCS1 is associated with memory performance. Three intron 1
SNPs (rs10884402, rs7078098 and rs950809) were associated in
the NIA-LOAD and Caribbean Hispanic datasets with memory
retention in single marker and haplotype analyses. In addition, all
three SNPs were significantly associated in a meta-analysis
including both datasets. When the analyses were stratified by
AD status, these associations were restricted to cases.
Our results are consistent with previous reports that genetic
variations in SORCS1 are associated with AD and could affect APP
processing [4,5,31]. Memory is the cognitive domain predomi-
nantly affected by AD, and is associated with changes in Ab levels
[32,33,34]. The three identified SNPs associated with memory
retention are in LD and it seems likely that they point to the same
disease associated variant. Of note, they are located between
108,782,932–108,785,365 bp in intron 1, and are thus in close
genetic distance to the SNPs that were associated with AD in our
Table 2. Single marker associations of SNPs rs10884402, rs7078098 and rs950809 with the memory savings score.
NIA-LOAD Caribbean Hispanics Meta-analysis
SNP name bp Role Alleles
minor
allele b SE P b SE P b p
ALL rs10884402 108,782,932 Intron 1 A/G A 20.10 0.07 0.129 20.15 0.06 0.008 20.13 0.003
rs7078098 108,783,778 Intron 1 C/T C 0.18 0.07 0.007 0.03 0.05 0.623 0.09 0.035
rs950809 108,785,365 Intron 1 C/T C 0.17 0.06 0.008 0.09 0.05 0.075 0.12 0.002
Controls rs10884402 108,782,932 Intron 1 A/G A 20.08 0.05 0.118 0.03 0.06 0.580 20.03 0.419
rs7078098 108,783,778 Intron 1 C/T C 0.09 0.05 0.092 20.03 0.06 0.562 0.03 0.407
rs950809 108,785,365 Intron 1 C/T C 0.09 0.05 0.090 20.02 0.06 0.681 0.04 0.326
Cases rs10884402 108,782,932 Intron 1 A/G A 20.21 0.28 0.463 20.15 0.07 0.026 20.15 0.019
rs7078098 108,783,778 Intron 1 C/T C 0.60 0.26 0.023 0.09 0.07 0.182 0.12 0.061
rs950809 108,785,365 Intron 1 C/T C 0.51 0.25 0.041 0.12 0.07 0.067 0.15 0.021
b=beta coefficient, SE=standard error, p=p-value. All models are adjusted for Population Stratification, sex, APOE-e4 and age-at-onset or age-at-examination. SNPs
significant at a 0.05 a-level are underlined. All p-values are corrected for multiple testing using the False Discovery Rate (FDR) [30].
doi:10.1371/journal.pone.0024588.t002
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SORCS1 and Cognition
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e24588previous report (located at 108,719,950–108,868,606 bp in intron
1), rs601883 reported by Li et al. [4] (at 108,904,435 bp in intron
1) and rs600879 reported by Grupe et al. (at 108,913,108 bp in
intron 1) [31]. The fact that the associations were present only in
cases in the stratified analyses suggests that the causative
variation(s) identify an endophenotype, cognitive decline, rather
that AD per se.
A limitation of this study is that we used only baseline measures
of cognition rather than change in cognition over time. However,
the principle of Mendelian Randomization in genetic association
studies overcomes the issue of reverse causation as the inheritance
of genetic variants is independent of -that is randomized with
respect to- the inheritance of other traits.
Although the identity of the specific AD and memory associated
sequence variations in SORCS1 remain to be determined, our
results support a role for SORCS1 in AD and suggest that genetic
variation in or close to intron 1 in SORCS1 might affect AD risk
and memory performance. Additional studies will be needed to
determine whether carriers of alleles associated with differential
risk for AD and cognitive performance are indeed protected and
that protection arises because of high levels of expression of
SorCS1.
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